Gain Therapeutics, Inc. (GANX) Stock Price & Analysis
Gain Therapeutics, Inc. (GANX) closed at USD 1.33 on Thursday, October 15, 2026, up 0.76% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.32; the Oct 15, 2026 session ranged USD 1.31–1.41 on volume of 501,270 shares. Market capitalization is $58.05M, with a 52-week range of USD 1.3–4.34 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GANX.md
Key facts (GANX)
- 1 of 80 tracked superinvestors hold GANX (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 7.2 (range 5–8).
- Total return with dividends: 1Y -26.5% vs S&P 500 +18.1%; 5Y -80.8% vs S&P 500 +85.1%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GANX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $165K | $140K | $55K | — | — | — |
| Operating income | -$13.8M | -$17.8M | -$22.3M | -$20.4M | -$18.7M | -$19.3M |
| Net income | -$13.9M | -$17.6M | -$22.3M | -$20.4M | -$20.2M | -$20.1M |
| EPS (diluted) | -$1.37 | -$1.48 | -$1.71 | -$0.89 | -$0.61 | — |
| Free cash flow | -$12.5M | -$14.8M | -$18.9M | -$18.9M | — | — |
| Operating margin | -8379.8% | -12688.1% | -40328.3% | — | — | — |
| Net margin | -8418.9% | -12555.1% | -40354.3% | — | — | — |
| Revenue growth | +471.3% | -15.1% | -60.6% | — | — | — |
| Cash + short-term investments | $36.9M | $20.1M | $16.8M | — | — | — |
| Total debt | $694K | $603K | $568K | $439K | $401K | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (GANX)
P/B 5.1x · Earnings yield -34.64% · Net cash $12.7M · EV $45.3M
Superinvestors (SEC 13F-HR, Q2 2026) (GANX)
1 of 80 tracked investors hold GANX. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| David Einhorn | Greenlight Capital | 0.03% | $1.1M | Unchanged |
Analysts (GANX)
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 7.2 (low 5, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-08-31 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-08-11 | BTIG | Reiterated | Buy | $5 |
| 2026-07-01 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-06-30 | BTIG | Maintained | Buy | $5 |
Total return (dividends reinvested) (GANX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -26.5% | -80.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -26.6% | -28.1% |
| Volatility (annualized) | 111.3% | 82.8% |
| Max drawdown | -68.4% (Dec 2025→Oct 2026) | -88.1% (Nov 2021→Aug 2024) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 1.33 |
|---|---|
| Change | ▲ 0.76% (up) |
| Previous Close | USD 1.32 |
| Open | USD 1.32 |
| Day Range | USD 1.31 – 1.41 |
| 52-Week Range | USD 1.3 – 4.34 |
| Volume | 501,270 shares |
| Market Cap | $58.05M |
| Exchange | NGM |
Technical Analysis (GANX)
Nexqual's technical model rates GANX "SELL" based on 3 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 23.86 (oversold) |
| vs SMA50 | Below (USD 1.8) |
| MACD | -0.1 (negative) |
Analyst Ratings (GANX)
Wall Street analysts rate GANX "Buy" based on 5 analysts, with a mean price target of USD 7.2 (range USD 5–8), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 7.2 |
| High Target | USD 8 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (GANX)
| EPS Estimate | USD -0.13 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.11 vs est -0.15 ▲ beat |
| 2026-03-31 | USD -0.13 vs est -0.14 ▲ beat |
| 2025-12-31 | USD -0.11 vs est -0.15 ▲ beat |
| 2025-09-30 | USD -0.15 vs est -0.15 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (GANX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -268.30% |
| Debt / Equity | 0.05 |
| Current Ratio | 4.36 |
| Total Cash | $13.08M |
| Total Debt | $609,874 |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (GANX)
Nexqual rates Gain Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $13M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$18M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -268%, ROA -95.5% |
Ownership (GANX)
| Insider Ownership | +2.23% |
|---|---|
| Institutional Ownership | +19.82% |
| Shares Outstanding | 43.64M |
| Float | 42.64M |
| Short % of Float | +7.16% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (GANX)
Gain Therapeutics, Inc. is led by Gene Mack (age 51), President, CEO, Director & Interim CFO, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO, Director & Interim CFO | Gene Mack (age 51) |
|---|---|
| Chairman & Founder | Khalid Islam (age 70) |
| Chief Operating Officer | Terenzio Ignoni Pharm.D. |
| Chief Scientific Officer | Joanne Taylor |
Major Backers & Investors (GANX)
Notable institutional backers of Gain Therapeutics, Inc. include Marshall Wace LLP, Potomac Capital Management, Inc., GSA Capital Partners LLP, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Marshall Wace LLP | 4.41% |
| Potomac Capital Management, Inc. | 2.17% |
| GSA Capital Partners LLP | 1.45% |
| Jones Financial Companies, L.L.L.P. | 1.39% |
| Cambridge Investment Research Advisors Inc. | 1.3% |
| DME Capital Management, LP | 1.3% |
| Fidelity | 0.86% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.62% |
| Geode Capital | 1.04% |
| BlackRock | 0.96% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt